Board of Directors

David Hallal

Chairman of the Board

David Hallal was appointed Chairman of iTeos Therapeutics in June 2018. He also currently serves as the Chairman of Scholar Rock (Nasdaq: SRRK) and is an independent director of Seer Biosciences.
David has 30 years of experience in the biopharmaceutical industry including over 10 years at Alexion Pharmaceuticals where he played a central role in transforming the company from the pre-commercial stage in 2006 to greater than $3 billion in annual revenue by 2016. As CEO of Alexion, David transitioned the company from a single-product to a multi-product enterprise. This included the US, EU, and Japan approval and the highly successful launch of Strensiq® and the rapid advancement of Alexion’s highest value pipeline candidate from a preclinical stage to registration trials in multiple diseases in just 18 months.
Prior to his appointment as CEO, David served as Alexion’s Chief Operating Officer and then Chief Commercial Officer, where he built the company’s commercial infrastructure and a 50-country operating platform which launched Soliris® for two ultra-rare diseases, Paroxysmal Nocturnal Hemoglobinuria and atypical Hemolytic Uremic Syndrome, resulting in the most successful commercialization of an ultra-orphan drug in the biotechnology industry. Prior to Alexion, David held commercial leadership positions at biopharmaceutical companies where he launched and expanded the adoption of numerous first-in-class and blockbuster products in hematology, oncology, nephrology, immunology and ophthalmology, as the Vice President of Sales at OSI Eyetech and at Biogen where he led the immunology sales team. Prior to Biogen, David also held various leadership roles at Amgen focused on the major oncology and hematology products Epogen®, Neupogen®, Neulasta® and Aranesp®. David holds a BA in Psychology from the University of New Hampshire.

Detlev Biniszkiewicz

Dr. Detlev Biniszkiewicz is a serial entrepreneur and an experienced biopharma executive who brings deep knowledge of oncology and immuno-oncology to his role at MPM. Currently, he is President and CEO of two early-stage biotech companies, Rekindle Therapeutics and NextPoint Therapeutics.

Prior to joining MPM, Detlev was the President and CEO of Surface Oncology (NASDAQ: SURF), where he led its growth and transformation through to clinical-stage and its preparation for a public offering. Prior to Surface Oncology, he was Vice President of Strategy in AstraZeneca’s Oncology Unit and was part of the oncology leadership that developed Lynparza® and Tagrisso®, two innovative medicines that help thousands of patients suffering from cancer. His group transformed AstraZeneca’s Oncology pipeline through numerous licensing deals, clinical and academic collaborations, and external research. Detlev has also held multiple roles at Novartis including Global Head of Portfolio, where his group provided oversight of Novartis’ research and early development portfolio. Detlev began his career at the Boston Consulting Group and performed his academic research at the Whitehead Institute for Biomedical Research at the Massachusetts Institute of Technology.

Aaron Davis

Aaron Davis is Co-Founder and Chief Executive Officer of Boxer Capital, LLC. In 2005, after joining Tavistock Group as Portfolio Manager, Mr. Davis scaled Tavistock Group’s public healthcare investing activities and formed Boxer Capital. Mr. Davis leads the firm’s research team, deal structuring, and portfolio management.

Mr. Davis is currently Chairman of the Board of CiVi Biopharma and is a Member of the Board of Directors of iTeos Therapeutics, Mirati Therapeutics, Odonate Therapeutics, Sojournix, Inc., and Tango Therapeutics.

Prior to joining Tavistock Group, Mr. Davis worked in the Global Healthcare Investment Banking and Private Equity Group at UBS Warburg, LLC. During this period, Mr. Davis led strategic transactions for public and private biotechnology and medical device companies throughout their growth, advising on financing and mergers and acquisitions. Having also served in various roles with biotechnology and venture capital firms, Mr. Davis has extensive expertise in investment analysis and in overseeing in-licensing activities within the pharmaceutical sector.

Mr. Davis holds a Master of Science in Biotechnology from Columbia University and a Bachelor of Arts in Business Administration from Emory University.

Michel Detheux

Chief Executive Officer

Michel has served as our Chief Executive Officer and a director since our inception. He previously served as a director at Ludwig Cancer Research from December 2010 to March 2012. Prior to that, Michel worked in various scientific and business development roles at Ogeda (f/k/a Euroscreen).

Michel holds a degree in biochemistry degree and a Ph.D. in Biochemistry from Université Catholique de Louvain and a business certificate from Solvay Business School. 

Derek DiRocco

Derek DiRocco is a Principal on the Investment Team at RA Capital Management. Derek works on both public and private investments and serves as a Board Director for 89Bio, Ltd. Previously, Derek covered solid tumor oncology landscapes. Derek holds a BA in Biology from Holy Cross College and a PhD in Pharmacology from the University of Washington. He conducted his postdoctoral research at Brigham and Women’s Hospital/Harvard Medical School, where he researched the role of the Wnt signaling pathway in mouse models of kidney disease, and was part of a team that discovered a stem cell subtype responsible for solid organ fibrosis.

Tim Van Hauwermeiren

Tim Van Hauwermeiren, M.Sc. EMBA, has been the Chief Executive Officer and an Executive Director at argenx SE since July 2008 and July 2014 respectively. Tim co-founded argenx in 2008 having previously served as the Senior Business Development Manager of Ablynx NV. Tim has more than 20 years of general management and business development experience across the life sciences and consumer goods sectors. Prior to joining Ablynx, he held various management positions with Procter & Gamble in R&D and Corporate New Business Development. Tim holds Bachelor and Master of Science degree in Bio-Engineering from the University of Ghent and received general management training at INSEAD. He also holds Executive MBA from the Vlerick School of Management.

Tony Ho

Dr. Tony Ho has nearly 20-years of comprehensive R&D experience in the biotechnology and pharmaceutical industry. He currently serves as Executive Vice President, Research and Development at CRISPR Therapeutics, where he leads R&D efforts across all product phases, including discovery, early and late-stage clinical development and regulation. Prior to joining CRIPSR, Dr. Ho held several roles of increasing seniority at AstraZeneca, most recently serving as the Senior Vice President and Head of Oncology Integration and Innovation. At AstraZeneca, he led the development and commercialization of two key drugs: LYNPARZA, a PARP inhibitor for ovarian cancer, and IMFINZI, a PD-L1 inhibitor and AstraZeneca’s first immuno-oncology drug for bladder cancer. Before that, Dr. Ho was the Neurology and Ophthalmology Clinical Section Head at Merck Research Laboratories, Merck & Co., and led multiple development programs, including the approval of Maxalt for pediatric migraine and Zioptan for glaucoma. Previously, he was the Co-Founder and Chief Scientific Officer of Neuronyx, a regenerative medicine company. Dr. Ho also currently serves on the Board of Directors of Engrail Therapeutics and is an adjunct Associate Professor at both the University of Pennsylvania and Johns Hopkins University. He earned his M.D. from the Johns Hopkins University School of Medicine and his B.S. in Electrical Engineering at the University of California, Los Angeles.

Robert Iannone

Dr. Robert Iannone, M.S.C.E., brings more than 16 years of experience in clinical drug development. He currently serves as Executive Vice President, Research and Development & Chief Medical Officer at Jazz Pharmaceuticals, where he oversees product development, clinical operations and regulatory affairs. Before that, Dr. Iannone was the Head of Research and Development and Chief Medical Officer of Immunomedics and held roles of increasing at AstraZeneca, where he most recently served as the Senior Vice President and Head of Immuno-oncology, Global Medicines Development and the Global Products Vice President. Previously, Dr. Iannone spent several years in management at Merck, culminating in his role as Executive Director and Section Head of Oncology Clinical Development. Earlier, he worked as an Assistant Professor of Pediatrics at the University of Pennsylvania School of Medicine. He earned his M.D. from Yale University and his B.S. from The Catholic University of America, and completed his pediatric residency, chief residency and pediatric hematology-oncology fellowship at the Johns Hopkins Hospital. Dr. Iannone also currently serves on the board of directors of Jounce Therapeutics.

Ann Rhoads

Ann Rhoads is a healthcare finance executive with over 25 years of experience. She was the Chief Financial Officer for Forty Seven, Inc. (Nasdaq:FTSV), a clinical stage, immuno-oncology company from 2018 until its sale to Gilead for $4.9 billion in 2020. From 2010 to early 2017, she was Executive Vice President and Chief Financial Officer at Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of orphan and central nervous system disorders.

Prior to joining Zogenix, Ms. Rhoads was Chief Financial Officer and Senior Vice President for Premier, Inc. from 2000 to 2009 (now Nasdaq:PINC). Ms. Rhoads started her career as an investment professional with Merrill Lynch and the Sprout Group, the venture capital affiliate of Donaldson, Lufkin & Jenrette (now part of Credit Suisse).

Ms. Rhoads received a Masters in Business Administration from the Harvard Graduate School of Business Administration and a Bachelor of Science in Business Administration from the University of Arkansas.

Matthew Roden

Dr. Matthew Roden is an Executive Partner at MPM.  Prior to joining MPM, Matt’s career spanned senior leadership in large pharma, the healthcare equity capital markets, and in basic science as an immunologist and structural biologist. Most recently, Matt was Senior Vice President and Head of Enterprise Strategy at Bristol Myers Squibb (BMS). In this role, Matt delivered the initial strategic plan for the company following its acquisition of Celgene. Earlier, he served as Head of Strategic Corporate Development, accountable for mergers and acquisitions, structured transactions, strategic equity investing, and divestitures, as well as Head of Global BD Assessment, leading business development search and evaluation activities for all therapeutic categories. Matt served on the R&D Leadership Team representing external innovation and led teams on over 100 business development transactions that are cumulatively valued at over $125 billion, including Bristol Myers Squibb’s acquisition of Celgene, the largest acquisition in the healthcare industry to date.

Before joining BMS, Matt was Head of Global Biotechnology Equity Research at UBS Investment Bank. Earlier, he was a Senior Equity Analyst covering biotechnology at J.P. Morgan and Bank of America Merrill Lynch, and was an Associate at Credit Suisse First Boston. In addition to his research coverage of the entire biotech sector, Matt and his teams provided equity research diligences and investor engagement on 24 Initial Public Offerings totaling $3.3bn in initial value from 2005-2016.

Matt has also served in advisory or Board capacities to several organizations, including biotechnology companies, investment funds, BIO, BioNJ, and the State of New Jersey.

Matt earned his Ph.D. at the Albert Einstein College of Medicine, focusing on the structural biology of immune-relevant molecules. This graduate work was preceded by his pre-doctoral clinical research fellowship in immuno-oncology at the National Cancer Institute in Bethesda, Maryland. Matt holds a M.S. degree from Georgetown University and a B.S. from George Mason University.